Certain glucose-lowering meds associated with lower risk for COPD exacerbations
For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...
The Lancet10h
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...